JP2022522650A5 - - Google Patents
Info
- Publication number
- JP2022522650A5 JP2022522650A5 JP2021548244A JP2021548244A JP2022522650A5 JP 2022522650 A5 JP2022522650 A5 JP 2022522650A5 JP 2021548244 A JP2021548244 A JP 2021548244A JP 2021548244 A JP2021548244 A JP 2021548244A JP 2022522650 A5 JP2022522650 A5 JP 2022522650A5
- Authority
- JP
- Japan
- Prior art keywords
- crispr
- activity
- cas effector
- polypeptide
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815179P | 2019-03-07 | 2019-03-07 | |
| US62/815,179 | 2019-03-07 | ||
| PCT/US2020/021214 WO2020181102A1 (en) | 2019-03-07 | 2020-03-05 | Crispr-cas effector polypeptides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522650A JP2022522650A (ja) | 2022-04-20 |
| JP2022522650A5 true JP2022522650A5 (enExample) | 2023-03-13 |
| JP7649748B2 JP7649748B2 (ja) | 2025-03-21 |
Family
ID=72338076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548244A Active JP7649748B2 (ja) | 2019-03-07 | 2020-03-05 | Ｃｒｉｓｐｒ－ｃａｓエフェクターポリペプチド及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12312614B2 (enExample) |
| EP (1) | EP3935155A4 (enExample) |
| JP (1) | JP7649748B2 (enExample) |
| CN (1) | CN114040971A (enExample) |
| WO (1) | WO2020181102A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| US10660419B2 (en) * | 2016-12-15 | 2020-05-26 | Elc Management Llc | Packaged skin treatment composition and method |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| WO2022072718A1 (en) | 2020-09-30 | 2022-04-07 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| AU2022284804A1 (en) | 2021-06-01 | 2023-12-07 | Arbor Biotechnologies, Inc. | Gene editing systems comprising a crispr nuclease and uses thereof |
| WO2024006824A2 (en) * | 2022-06-28 | 2024-01-04 | Mammoth Biosciences, Inc. | Effector proteins, compositions, systems and methods of use thereof |
| EP4622662A1 (en) | 2022-11-23 | 2025-10-01 | Amber Bio Inc. | Gene-modifying endonucleases |
| CN120569476A (zh) | 2022-11-30 | 2025-08-29 | 安铂生物公司 | 用于靶向反式剪接的方法和组合物 |
| US20260232844A1 (en) | 2023-02-15 | 2026-08-13 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
| US12655424B2 (en) | 2024-02-05 | 2026-06-16 | Amber Bio Inc. | Methods and compositions for trans-splicing utilizing small nuclear RNAs and small nucleolar RNAs |
| WO2025171210A1 (en) | 2024-02-09 | 2025-08-14 | Arbor Biotechnologies, Inc. | Compositions and methods for gene editing via homology-mediated end joining |
| WO2026015829A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Small reverse transcriptases and gene editing systems comprising such |
| WO2026015832A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Reverse transcriptases and gene editing systems comprising such |
| CN119372181B (zh) * | 2024-09-14 | 2026-05-19 | 上海尧唐生物科技股份有限公司 | 一种核酸酶蛋白及其应用 |
| US12686869B1 (en) | 2026-01-23 | 2026-07-21 | Amber Bio Inc. | Methods and compositions for trans-splicing utilizing trifunctional elements |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605709B1 (en) * | 1999-04-09 | 2003-08-12 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| AU2004271200A1 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| EP3702460A1 (en) * | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| CA2932439A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP4159848A1 (en) * | 2015-12-29 | 2023-04-05 | Monsanto Technology LLC | Novel crispr-associated transposases and uses thereof |
| CA3026110A1 (en) * | 2016-04-19 | 2017-11-02 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US11692184B2 (en) * | 2017-05-16 | 2023-07-04 | The Regents Of The University Of California | Thermostable RNA-guided endonucleases and methods of use thereof |
| GB201712733D0 (en) * | 2017-08-08 | 2017-09-20 | Snipr Tech Ltd | Methods & cells |
-
2020
- 2020-03-05 EP EP20767083.7A patent/EP3935155A4/en active Pending
- 2020-03-05 JP JP2021548244A patent/JP7649748B2/ja active Active
- 2020-03-05 WO PCT/US2020/021214 patent/WO2020181102A1/en not_active Ceased
- 2020-03-05 CN CN202080030261.1A patent/CN114040971A/zh active Pending
-
2021
- 2021-08-16 US US17/403,236 patent/US12312614B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017018125A5 (enExample) | ||
| JP7559005B2 (ja) | 真核ゲノム修飾のための操作されたＣａｓ９システム | |
| JP2023541400A5 (enExample) | ||
| JP2024083479A5 (enExample) | ||
| US20190382775A1 (en) | Truncated crispr-cas proteins for dna targeting | |
| JP2022526695A (ja) | 遺伝子編集における非意図的な変異の阻害 | |
| JP2022519507A5 (enExample) | ||
| JP7649748B2 (ja) | Ｃｒｉｓｐｒ－ｃａｓエフェクターポリペプチド及びその使用方法 | |
| JP2023516226A5 (enExample) | ||
| JP2025102784A5 (enExample) | ||
| WO2022056254A3 (en) | Dna modifying enzymes and active fragments and variants thereof and methods of use | |
| JP2023549339A5 (enExample) | ||
| CN110139927A (zh) | Crispr-cas9抑制剂 | |
| CA2956224A1 (en) | Cas9 proteins including ligand-dependent inteins | |
| EP2855671A2 (en) | New transcription activator-like effector (tale) fusion protein | |
| AR125191A1 (es) | Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso | |
| US20230242627A1 (en) | Composition and method for activating latent human immunodeficiency virus (hiv) | |
| WO2024198961A1 (zh) | 一种Cas蛋白及其突变体、其相应的基因编辑系统及应用 | |
| JP2024543042A5 (enExample) | ||
| JP2024531607A5 (enExample) | ||
| JP2026515554A (ja) | Ｃｒｉｓｐｒの干渉および活性化のための改善された方法および組成物 | |
| WO2026011782A1 (zh) | 抑制FXI基因表达的siRNA的制备方法 | |
| JP7249620B2 (ja) | 核酸結合因子 | |
| US20060172373A1 (en) | Mutant Recombinases | |
| KR102935503B1 (ko) | 신규 Cas12a 단백질, 신규 Cas12a 단백질의 변형체 및 이들의 진핵세포 유전체 편집 용도 |